Renal Impairment Considerations for Candesartan Use

Introduction to Renal Impairment and Candesartan

The American Heart Association recommends holding candesartan in patients with impaired renal function and reassessing blood work before considering restarting the medication, as angiotensin receptor blockers (ARBs) like candesartan can cause significant adverse effects in these patients 1
ARBs can cause worsening of renal function, particularly in patients whose renal function depends on the renin-angiotensin system, highlighting the need for careful consideration in patients with pre-existing renal issues 2

Patients with impaired renal function taking ARBs are at risk of hyperkalemia, a common complication that necessitates close monitoring of serum electrolytes, particularly potassium 1
The European Society of Cardiology suggests checking current renal function parameters, including serum creatinine, estimated glomerular filtration rate (eGFR), and serum electrolytes, to evaluate the severity of renal impairment 3
The severity of renal impairment should be evaluated based on creatinine clearance (CrCl), with mild impairment (CrCl 60-90 ml/min) requiring no dose adjustment, moderate impairment (CrCl 30-60 ml/min) requiring closer monitoring, and severe impairment (CrCl ≤30 ml/min) having safety not established 3

Candesartan should be held immediately if serum creatinine rises to >310 μmol/L (>3.5 mg/dL), potassium rises to >6.0 mmol/L, the patient shows signs of acute kidney injury, or the patient has severe renal impairment (CrCl ≤30 ml/min) 3
After holding candesartan, it is recommended to monitor blood chemistry closely, reassess renal function and electrolytes within 3-7 days, and consider specific treatment of renal dysfunction if needed 3
If renal function improves and stabilizes, consider restarting candesartan at a lower dose (4 mg daily) and monitor renal function and electrolytes within 1 week of restarting, with cautious dose titration if necessary 1, 4

Patients with bilateral renal artery stenosis are at particularly high risk for worsening renal function with ARBs, necessitating careful consideration and monitoring 5
The American College of Cardiology advises against combining an ARB with both an ACE inhibitor and aldosterone antagonist due to the high risk of renal dysfunction and hyperkalemia 1